Forecast: Business Enterprise R&D Expenditure in Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations in Japan

In 2023, Japan's business enterprise R&D expenditure in the manufacture of basic pharmaceutical products and pharmaceutical preparations stood at 13.67 billion US dollars in PPP terms. The forecast for 2024 is 13.85 billion, representing a growth of approximately 1.32%. Subsequently, a steady year-on-year increase is projected, with 1.30% in 2025, 1.29% in 2026, 1.27% in 2027, and 1.25% in 2028. Over the five-year forecast period (2024-2028), the compound annual growth rate (CAGR) stands at 1.29%, indicating a modest and consistent upward trend in R&D expenditure.

• Key factors driving this growth include technological advancements, regulatory changes, and increased focus on innovative drug development.
• Future trends to watch for encompass the impact of digital transformation, personalized medicine, and potential shifts in regulatory or economic landscapes.